varithena- polidocanol kit
biocompatibles, inc. - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - polidocanol 180 mg in 1 ml - varithena (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (gsv) system above and below the knee. varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. the use of varithena is contraindicated in patients with: - known allergy to polidocanol [see warnings and precautions (5.1)] - acute thromboembolic disease risk summary few published case reports with use of polidocanol-containing products, including varithena, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although no risks have been identified, there is minimal benefit in treating lower extremity varicosities during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. in animal reproduction studies, no adverse develo
polidocanol 3 % vijosa solución inyectable
laboratorios vijosa, s.a. de c.v. - polidocanol - polidocanol....30.00 mg
asclera- polidocanol injection, solution
merz north america, inc - polidocanol (unii: 0awh8bfg9a) (polidocanol - unii:0awh8bfg9a) - polidocanol 0.01000 g in 1 ml - asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. asclera has not been studied in varicose veins more than 3 mm in diameter. asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. risk summary the available data from case reports on use of polidocanol-containing products, including asclera, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. the animal reproduction studies were conducted in a manner to achieve systemic e
varithena polidocanol injectable foam 10mgml
transmedic pte ltd - polidocanol - injection - polidocanol 10mg/ml
lidocan- lidocaine 5% patch
puretek corporation - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocan™ is indicated for relief of pain associated with post-herpetic neuralgia. it should be applied only to intact skin. lidocan™ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
lidocan iii- lidocaine 5% patch
puretek corporation - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocan™ iii is indicated for relief of pain associated with post-herpetic neuralgia. it should be applied only to intact skin. lidocan™ iii is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
balneum plus
neopharm ltd - polidocanol; soya oil - solution - soya oil 82.95 g / 100 g; polidocanol 15 g / 100 g - polidocanol - polidocanol - refatting medical oil bath with antipruritic effect.
lidocan ii
puretek corporation - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocan™ ii is indicated for relief of pain associated with post-herpetic neuralgia. it should be applied only to intact skin. lidocan™ ii is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
lidocan iv- lidocaine 5% patch
puretek corporation - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocan™ iv is indicated for relief of pain associated with post-herpetic neuralgia. it should be applied only to intact skin. lidocan™ iv is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
lidocan v- lidocaine 5% patch
puretek corporation - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocan™ v is indicated for relief of pain associated with post-herpetic neuralgia. it should be applied only to intact skin. lidocan™ v is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.